PersonaDx

At PersonaDx, we are reshaping cancer care through molecular genetics and AI-driven clinical risk assessment. Our innovative platform revolutionizes oncology with unmatched 96% accuracy in colorectal tumor classification, informing metastatic cancer prognosis and delivering personalized treatment solutions to improve patient outcomes and overall quality of life. The only clinically validated, metastasis-specific biomarker: PersonaDx addresses metastatic colorectal cancer (CRC) with the first and only test of its kind. 96% accuracy: Revolutionizing prognostic precision with neural network validation. Risk-based stratification: Stratifies patients into risk groups by integrating disease biology with clinical data. Improved outcomes: Avoids unnecessary treatments, reduces costs, and enhances overall survival rates. Validated in clinical trials: Supported by Phase 3 New-EPOC trial results for proven success. Comprehensive molecular insights: Offers both 31-gene (mRNA and microRNA) and 150-gene (mRNA only) biomarker assays adaptable to various sequencing platforms, providing actionable data for personalized care. Focused on patient impact: Designed for patients with colorectal cancer metastases confined to the liver, enabling better-informed therapy decisions for improved survival and potential cure. Discover the full details of how PersonaDx can enhance personalized care and improve outcomes. For comprehensive information about this groundbreaking test, or to schedule a meeting to discuss our tests with Leadership, send an email to: ✉️ info@persona-dx.com